ILOTYCIN GLUCEPTATE
Pre-Launcherythromycin gluceptate
NDAINJECTIONINJECTABLE
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ILOTYCIN GLUCEPTATE is an injectable formulation of erythromycin gluceptate, a macrolide antibiotic administered via injection for systemic infections. The drug works by inhibiting bacterial protein synthesis, making it suitable for patients requiring parenteral antibiotic therapy. This is a legacy product in pre-launch development status.
Pre-Launch
Pre-launch status suggests this product remains exploratory with minimal commercial infrastructure and team size currently undefined.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ILOTYCIN GLUCEPTATE would primarily involve regulatory pathway development, competitive positioning, and pre-commercial planning rather than established commercial execution. This represents a foundational opportunity for professionals interested in drug development strategy or injectable antibiotic markets.
Product ManagerRegulatory Affairs Specialist
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.